JPWO2021247430A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021247430A5 JPWO2021247430A5 JP2022572558A JP2022572558A JPWO2021247430A5 JP WO2021247430 A5 JPWO2021247430 A5 JP WO2021247430A5 JP 2022572558 A JP2022572558 A JP 2022572558A JP 2022572558 A JP2022572558 A JP 2022572558A JP WO2021247430 A5 JPWO2021247430 A5 JP WO2021247430A5
- Authority
- JP
- Japan
- Prior art keywords
- administered
- dose
- fusion polypeptide
- individual
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063033074P | 2020-06-01 | 2020-06-01 | |
| US63/033,074 | 2020-06-01 | ||
| US202063106285P | 2020-10-27 | 2020-10-27 | |
| US63/106,285 | 2020-10-27 | ||
| US202063109083P | 2020-11-03 | 2020-11-03 | |
| US63/109,083 | 2020-11-03 | ||
| US202063114959P | 2020-11-17 | 2020-11-17 | |
| US63/114,959 | 2020-11-17 | ||
| US202163145925P | 2021-02-04 | 2021-02-04 | |
| US63/145,925 | 2021-02-04 | ||
| PCT/US2021/034967 WO2021247430A1 (en) | 2020-06-01 | 2021-05-28 | Combination therapies comprising a hypomethylation agent for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023528341A JP2023528341A (ja) | 2023-07-04 |
| JPWO2021247430A5 true JPWO2021247430A5 (https=) | 2024-06-04 |
| JP2023528341A5 JP2023528341A5 (https=) | 2024-06-04 |
Family
ID=76808133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022572558A Pending JP2023528341A (ja) | 2020-06-01 | 2021-05-28 | 低メチル化剤を含むがんを治療するための併用療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12343377B2 (https=) |
| EP (1) | EP4157315A1 (https=) |
| JP (1) | JP2023528341A (https=) |
| KR (1) | KR20230018475A (https=) |
| CN (1) | CN115666620A (https=) |
| AU (1) | AU2021283083A1 (https=) |
| CA (1) | CA3178157A1 (https=) |
| IL (1) | IL298644A (https=) |
| MX (1) | MX2022014784A (https=) |
| WO (1) | WO2021247430A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106146670B (zh) * | 2015-04-24 | 2019-01-15 | 宜明昂科生物医药技术（上海）有限公司 | 一种新的重组双功能融合蛋白及其制备和应用 |
| WO2017027422A1 (en) | 2015-08-07 | 2017-02-16 | Alexo Therapeutics Inc. | Constructs having a sirp-alpha domain or variant thereof |
| BR112021024003A2 (pt) * | 2019-05-31 | 2022-04-19 | Alx Oncology Inc | Métodos de tratamento de câncer com fusão sirp alfa-fc em combinação com um inibidor de checkpoint imunológico |
| AU2020394204A1 (en) | 2019-11-27 | 2022-06-02 | ALX Oncology Inc. | Combination therapies for treating cancer |
| US12343377B2 (en) | 2020-06-01 | 2025-07-01 | ALX Oncology Inc. | Combination therapies comprising a hypomethylation agent for treating cancer |
| JP2024520902A (ja) | 2021-05-13 | 2024-05-27 | エーエルエックス オンコロジー インコーポレイテッド | がんを治療するための併用療法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2804617T1 (sl) | 2012-01-17 | 2020-10-30 | The Board Of Trustees Of The Leland Stanford Junior University | Visokoafinitetni SIRP-alfa reagenti |
| ES2914814T3 (es) | 2012-12-17 | 2022-06-16 | Pf Argentum Ip Holdings Llc | Tratamiento de células enfermas CD47+ con fusiones SIRP Alfa-Fc |
| TWI759810B (zh) | 2014-08-08 | 2022-04-01 | 美商Ａｌｘ腫瘤技術股份有限公司 | 信號調節蛋白α(signal-regulatory proteinα, SIRP-α)變體構築物及其用途 |
| EP3012271A1 (en) | 2014-10-24 | 2016-04-27 | Effimune | Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases |
| CN106146670B (zh) | 2015-04-24 | 2019-01-15 | 宜明昂科生物医药技术（上海）有限公司 | 一种新的重组双功能融合蛋白及其制备和应用 |
| CA2994935A1 (en) | 2015-05-18 | 2016-11-24 | Ab Initio Biotherapeutics, Inc. | Sirp polypeptide compositions and methods of use |
| WO2017027422A1 (en) | 2015-08-07 | 2017-02-16 | Alexo Therapeutics Inc. | Constructs having a sirp-alpha domain or variant thereof |
| JP7078533B2 (ja) | 2015-10-21 | 2022-05-31 | オーエスイー イムノセラピューティクス | 炎症促進性細胞へのマクロファージ分極を改変して癌を治療するための抗ＳＩＲＰａ化合物 |
| SG11201808465UA (en) | 2016-04-14 | 2018-10-30 | Ose Immunotherapeutics | NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS |
| AU2017250029C1 (en) | 2016-04-15 | 2022-03-24 | Pfizer Inc. | Macrophage stimulation in CD47 blockade therapy |
| KR102878970B1 (ko) | 2016-08-03 | 2025-10-30 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항-SIRPalpha 항체 요법의 대식세포 증진 효능에서 Fc 수용체 참여의 붕괴 |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| CA3042581A1 (en) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Enhancement of cd47 blockade therapy by proteasome inhibitors |
| WO2018081898A1 (en) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Improvements in cd47 blockade therapy by hdac inhibitors |
| CN118027200A (zh) | 2016-12-09 | 2024-05-14 | 艾利妥 | 抗SIRPα抗体及其使用方法 |
| JP7179743B2 (ja) | 2017-02-17 | 2022-11-29 | オーエスイー・イミュノセラピューティクス | 抗ＳＩＲＰｇ抗体の新規の使用 |
| CA3057718A1 (en) | 2017-03-28 | 2018-10-04 | Trillium Therapeutics Inc. | Cd47 blockade therapy |
| CN118267470A (zh) | 2017-04-13 | 2024-07-02 | 赛罗帕私人有限公司 | 抗SIRPα抗体 |
| CN118271443A (zh) | 2017-05-16 | 2024-07-02 | 拜奥迪斯私人有限公司 | 抗SIRPα抗体 |
| WO2019023347A1 (en) | 2017-07-26 | 2019-01-31 | Forty Seven, Inc. | ANTI-SIRP-ALPHA ANTIBODIES AND ASSOCIATED METHODS |
| WO2020047326A2 (en) | 2018-08-31 | 2020-03-05 | ALX Oncology Inc. | Decoy polypeptides |
| BR112021024003A2 (pt) | 2019-05-31 | 2022-04-19 | Alx Oncology Inc | Métodos de tratamento de câncer com fusão sirp alfa-fc em combinação com um inibidor de checkpoint imunológico |
| CN114206912B (zh) | 2019-06-07 | 2025-02-11 | Alx肿瘤生物技术公司 | 用于在血清学测定中减少结合cd47的药物的干扰的方法和试剂 |
| CN114555123B (zh) | 2019-10-18 | 2024-04-02 | 四十七公司 | 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法 |
| AU2020394204A1 (en) | 2019-11-27 | 2022-06-02 | ALX Oncology Inc. | Combination therapies for treating cancer |
| US12343377B2 (en) | 2020-06-01 | 2025-07-01 | ALX Oncology Inc. | Combination therapies comprising a hypomethylation agent for treating cancer |
| WO2022010806A1 (en) | 2020-07-06 | 2022-01-13 | ALX Oncology Inc. | Methods for reducing the interference of drugs that bind therapeutic targets expressed on blood cells in serological assays |
| WO2022120286A1 (en) | 2020-12-06 | 2022-06-09 | ALX Oncology Inc. | Multimers for reducing the interference of drugs that bind cd47 in serological assays |
| JP2024520902A (ja) | 2021-05-13 | 2024-05-27 | エーエルエックス オンコロジー インコーポレイテッド | がんを治療するための併用療法 |
-
2021
- 2021-05-28 US US17/334,151 patent/US12343377B2/en active Active
- 2021-05-28 AU AU2021283083A patent/AU2021283083A1/en not_active Abandoned
- 2021-05-28 JP JP2022572558A patent/JP2023528341A/ja active Pending
- 2021-05-28 WO PCT/US2021/034967 patent/WO2021247430A1/en not_active Ceased
- 2021-05-28 EP EP21739202.6A patent/EP4157315A1/en active Pending
- 2021-05-28 KR KR1020227046227A patent/KR20230018475A/ko not_active Withdrawn
- 2021-05-28 MX MX2022014784A patent/MX2022014784A/es unknown
- 2021-05-28 IL IL298644A patent/IL298644A/en unknown
- 2021-05-28 CA CA3178157A patent/CA3178157A1/en active Pending
- 2021-05-28 CN CN202180039242.XA patent/CN115666620A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12377144B2 (en) | Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen | |
| Ashkenazi et al. | Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin. | |
| JP7715635B2 (ja) | イズロン酸２－スルファターゼを含むタンパク質分子の製剤 | |
| JP2021526512A5 (https=) | ||
| US20220177550A1 (en) | Chimeric proteins and chimeric protein complexes directed to fms-like tyrosine kinase 3 (flt3) | |
| CN106536562A (zh) | 来那度胺或泊利度胺与经抗CD38抗体灭毒的干扰素α构筑体的组合，和其用途 | |
| JP2019530434A5 (https=) | ||
| JP2022512722A (ja) | 抗ｃｄ３８抗体の皮下投与を提供する方法 | |
| CA3152776A1 (en) | Pharmaceutical formulations and dosage regimens for multi-specific binding proteins that bind her2, nkg2d, and cd16 for cancer treatment | |
| JP2009541492A5 (https=) | ||
| JP2002514201A (ja) | 凝固および腫瘍の処置のための組織因子の方法および組成物 | |
| AU2009321252A1 (en) | Antitumor combinations containing antibodies recognizing specifically CD38 and cylophosphamide | |
| CN85107562A (zh) | 含蒽环糖苷药物组合物的制备方法 | |
| EP4277707A1 (en) | Interferon prodrugs and methods of making and using the same | |
| CA3173919A1 (en) | Use of a multimeric anti-dr5 binding molecule in combination with a cancer therapy for treating cancer | |
| JPWO2021108693A5 (https=) | ||
| JPWO2021247430A5 (https=) | ||
| CN119424632A (zh) | 治疗结直肠癌的联用药物组合物 | |
| TW201801746A (zh) | Cd33抗體藥物結合物與化學治療劑之組合 | |
| JP2023162163A (ja) | 抗ｃｄ３０抗体薬物複合体療法の副作用を軽減する方法 | |
| US20240327483A1 (en) | Fusion proteins comprising suppression of tumorigenicity 2 or interleukin-33, pharmaceutical compositions, and therapeutic applications | |
| JPWO2020243338A5 (https=) | ||
| JPWO2023151693A5 (https=) | ||
| JPWO2022241157A5 (https=) | ||
| JPWO2022188832A5 (https=) |